• Home
• Media centre
• Press kits
• Avandia press kit

Avandia press kit: more information

• Press kit
• More information

The information on this page is intended for business journalists and analysts/investors.

This page provides various press releases and background documents about Avandia (rosiglitazone maleate).

 

Press releases

2008
• 8 April 2008 - GlaxoSmithKline confirms receipt of FDA letter on regulatory reporting
• 6 February 2008 - GlaxoSmithKline responds to findings in ACCORD study
• 24 January 2008 - GlaxoSmithKline to revise Avandia® (rosiglitazone maleate) label in Europe following assessment by CHMP

2007
• 11 December 2007 - GlaxoSmithKline responds to JAMA article on the ICES thiazolidinediones and cardiovascular outcomes in older patients with diabetes
• 4 December 2007 - Statement from GlaxoSmithKline: publication of update regarding thiazolidinediones to treatment guidelines for the management of type 2 diabetes mellitus by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA)
• 3 December 2007 - GSK response to Nature Medicine article on rosiglitazone and bone in mice
• 14 November 2007 - GlaxoSmithKline revises US labeling for Avandia®
• 11 September 2007 - GlaxoSmithKline responds to JAMA articles
• 14 August 2007 - GlaxoSmithKline updates prescribing information for Avandia® in the US (PDF 49Kb)
• 30 July 2007 - FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
• 30 July 2007 - GlaxoSmithKline presents Avandia data to FDA
• 27 July 2007 - GlaxoSmithKline statement in diabetes care study thiazolidinediones and heart failure: a teleo-analysis
• 17 July 2007 - GSK responds to online review of rosiglitazone by The Cochrane Collaboration
• 16 July 2007 - GSK responds to reviews of oral diabetes medications (PDF 98Kb)
• 24 June 2007 - Data shows Avandia patients incur lower medical costs and use fewer healthcare resources
• 6 June 2007 - Newly published data from large study support cardiovascular safety of Avandia (rosiglitazone maleate)
• 5 June 2007 - GSK response to New England Journal of Medicine editorials
• 5 June 2007 - Data from GSK's RECORD study published in NEJM
• 30 May 2007 - Data affirms Avandia cardiovascular safety profile
• 21 May 2007 - GSK response to NEJM article
• 21 May 2007 - GSK response to US Senate Committee on Finance

 

Additional Background Information

• Avandia: Consumer update from US FDA
• Avandia: FDA information for healthcare professionals (PDF 35Kb)
• Avandia: FDA statement on safety alert (PDF 20Kb)
• Avandia: The Lancet editorial (PDF 64Kb)
• 30 July 2007 - Diabetes complications report (PDF 479Kb)
• 30 July 2007 - FDA consumer update
• 30 July 2007 - FDA healthcare professionals (PDF 35Kb)

Letters of testimony

• 30 January 2008 - GSK responds to letter from Senator Grassley (PDF 71Kb)
• 12 June 2007 - GSK CEO's response to editorial in USA Today (PDF 17Kb)
• 6 June 2007 - Statement of Moncef Slaoui, PhD, Chairman Research & Development, GlaxoSmithKline (PDF 382Kb)
• 30 May 2007 - GSK letter published by The Lancet

 

Back to top